| INTRODUC TI ON
Gastric cancer is one of the most common gastrointestinal cancers worldwide.
1,2 Although early diagnostic rates have improved due to the widespread use of gastroscopy, the prognosis for advanced patients with gastric cancer remains very poor, with a 5-year survival rate of less than 25%. [3] [4] [5] Furthermore, gastric carcinogenesis is a complicated process, resulting from the dysregulation of numerous tumor-related genes. Therefore, more ideal biomarkers for the diagnosis of gastric cancer are urgently needed. Improved understanding of the molecular mechanisms underlying gastric carcinogenesis will enhance diagnosis and treatment of gastric cancer.
Metabolism is defined as the chemical reactions in living
organisms by which energy is provided for life-sustaining activities and new materials are assimilated. Altered metabolism, a hallmark of cancers, contributes to cancers from initiation, growth, development, and maintenance to malignant transformation. 6 Identifying these metabolic alterations and regulatory mechanisms in cancers may reveal a new avenue for therapeutic intervention.
Cancer cells prefer to utilize glucose to produce energy under aerobic or anaerobic conditions, with an associated rise in lactate production. The phenomenon of aerobic glycolysis is termed the Warburg effect. 6 To date, the mammalian glucose transporter (GLUT)
family, which is associated with glycolysis, is classified into three subfamilies: class 1 (GLUT-1, -2, -3, -4, and GLUT-14), class 2 (GLUT-5, -7, -9, and -11), and class 3 (GLUT-6, -10, -12, and -13). 7, 8 Several studies have indicated that GLUT-1 and GLUT-14 are independent prognostic factors for gastric cancer. [9] [10] [11] In addition, GLUT-4 is upregulated by P38 MAPK signaling and enhances glycolysis in gastric cancer cells. 12 Metastasis associated with colon cancer-1 (MACC1), a long noncoding RNA (lncRNA), enhances the Warburg effect by increasing the activities and upregulating the expression of several glycolytic enzymes in gastric cancer cells. 13 Moreover, amino acid metabolism is changed in gastric carcinoma. For example, cysteine, serine, isoleucine, tyrosine, and others are increased in gastric cancer. 14 Furthermore, blood valine levels were significantly altered in patients with gastric cancer.
15
LncRNAs are transcripts longer than 200 nucleotides with nonprotein coding functions. 16, 17 They are divided into antisense, sense, bidirectional, intronic, and intergenic categories. 18 LncRNAs play important roles in cancer incidence and development.
19-24
Furthermore, lncRNAs regulate metabolism in cancer cells. For example, lincRNA p21 modulates glycolysis, 25 and urothelial cancer-associated 1 (UCA1) regulates glycolysis by upregulating hexokinase 2 (HK2), a key enzyme in the glycolytic pathway. 26 In hepatoma cells, the lncRNA highly upregulated in liver cancer (HULC) regulates lipid metabolism.
27
To understand the metabolic regulatory roles of lncRNAs in gastric cancer, we analyzed aberrantly expressed metabolic pathwayassociated lncRNAs and examined their potential diagnostic values in gastric cancer. 
| MATERIAL S AND ME THODS

| Sample collecting
| RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's protocol.
Quality and quantification of RNA were evaluated using a DS-11+
Spectrophotometer (DeNovix, Wilmington, DE). OD 260/280 values approximately 1.8 were regarded as a criterion for acceptable levels.
Total RNA was stored at −80°C until use. 
| Analysis of metabolic pathwayassociated lncRNAs
| qRT-PCR detection of RP11-555H23.1
To confirm the results of the lncRNA microarray, cDNA was reverse tran- 
| Sequencing of qRT-PCR products
To determine the validity of qRT-PCR results, we first used a UNIQ-10 PCR product purification kit (Sangon Biotech, Shanghai, China) to purify PCR products and then cloned them into the pUCm-T vector (Sangon Biotech). 23 Finally, sequencing was performed by Tsingke Biotech Co., Ltd., Hangzhou, China.
| Serological biomarker analysis
An Elecsys 2010 machine (Roche Diagnostics, Basel, Switzerland) was used to detect serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) levels. Their cutoff values were set at 35 U/mL and 5 ng/mL, respectively.
| Statistical analysis
Statistical Program for Social Sciences (SPSS) 18.0 software (SPSS, Chicago, IL) was used for all data analysis. Differences in the RP11-555H23.1 expression levels between cancer tissues and paired nontumor tissues were evaluated using paired sample t test.
Relationships between the RP11-555H23.1 levels and clinicopathological features of the gastric cancer patients were further analyzed by a two-tailed Student's t test, rank-sum test, or one-way analysis of variance (ANOVA). To assess diagnostic value, a receiver operating characteristic (ROC) curve was created. The statistical significance was set at P < 0.05.
| RE SULTS
| Global metabolic pathway-associated lncRNA expression patterns in gastric cancer
Volcano plots are useful tools for visualizing differential expression of metabolic pathway-associated lncRNAs between gastric cancer tissues and paired nontumor tissues ( Figure S1 ). Microarray detection data showed that, of 114 metabolic pathway-associated lncRNAs, 51 downregulated lncRNAs (Table 1 ) and 63 upregulated lncRNAs (Table 2) were significantly differentially expressed between the gastric cancer and adjacent nontumor tissues (fold change >2.0, P < 0.05; GEO accession number 96856: https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE96856). The lowest expressed lncRNAs in the gastric cancer group were TUG1, RP11-555H23.1, RP1-257I20.13, UGP2, GCSHP3, and XLOC_000889 (Table 1) .
The highest expressed lncRNAs in the gastric cancer group were RP11-605F14.2, TBC1D3P5, BC130595, LINC00475, RP11-19P22.6, BC080653, XLOC_004923, AFAP1-AS1, EPB49, and RP11-296I10.3 (Table 2 ).
| Expression of RP11-555H23.1 is reduced in gastric cancer samples
In our previous experiments, we found that expression of TOPORS antisense RNA 1 (TOPORS-AS1) in expanded sample numbers of gastric cancer tissues was consistent with our microarray results ( gastric cancer cell lines. 24 In this study, RP11-555H23.1 was chosen to confirm the microarray results. RP11-555H23.1, a newly discovered lncRNA, is transcribed from the antisense strand of chromosome X, and there are no reports regarding its expression in cancers. In the microarray results, the expression patterns of three patients between gastric cancer and nontumor tissues were the same. As illustrated in the microarray results (Table 1) r=X:5305714-5307128;t=ENST00000434972).
| Possible diagnostic value of RP11-555H23.1 in gastric cancer
We next investigated whether RP11-555H23.1 expression is related to the clinicopathological features of gastric cancer. Using another 104 pairs of gastric carcinoma tissues and the adjacent noncancer tissues, we found that levels of RP11-555H23.1 are correlated with TNM stage (P = 0.038; Table 3 ). Patients at Stage IV are typically not candidates for surgery, and obtaining cancer tissues for study is difficult. Among patients in this study, 11 suffered from metastatic gastric cancer. Eight of them developed pyloric obstruction and could not eat, necessitating surgery. Three other patients did not exhibit distant metastases during preoperative examination.
However, in the middle of the surgery, these patients were found to have distant metastases, one hepatic metastasis and two peritoneal implantation metastases. Since the number of patients with Stage IV disease was small (11 patients), we pooled Stage III and Stage IV patients (Table 3) . Although there was no significant difference in the results of the pT, pN, and M analyses (Table 3) , a significant difference for the TNM stage was observed, and TNM staging, which uses combinations of pT, pN, and M, indicates the extent of cancer spread.
Furthermore, an ROC curve was constructed by grouping gastric cancer and nontumor samples to assess the diagnostic value of RP11-555H23.1. The area under the ROC (AUR) curve was 0.65 ( Figure 2) , and further analysis showed that, at a cutoff of 12.9 (ΔC q value), sensitivity and specificity were 81% and 62%, respectively. 
| D ISCUSS I ON
Cancer is a class of diseases involving oncogene activation and tumor suppressor gene inhibition. In recent years, deep sequencing studies including large consortia and advances in technology, such as RNA deep sequencing and tiling arrays, have enabled identification of abundant tumor-associated coding sequences and noncoding sequences. 28, 29 In particular, lncRNAs have received increasing attention. Current knowledge regarding the functions of lncRNAs has shown that they are involved in a diversity of cancer-associated processes. 30 For example, LINC00982 regulates cell proliferation in gastric cancer. 31 Moreover, another lncRNA, FOXP4 antisense RNA 1 (FOXP4-AS1), is overexpressed in colorectal cancer tissues and significantly related to TNM stages and regulation of cell proliferation. In our study, the metabolic pathway-associated lncRNAs in gastric cancer were studied for the first time. A total of 114 differentially expressed lncRNAs between gastric cancer tissues and paired nontumorous tissues were found (Tables 1 and 2 ). Some of these lncRNAs have been found to play crucial roles in carcinogenesis. For example, RP11-19P22.6-001 and its target, nitric oxide synthase 2 (NOS2), are associated with gastric cancer, and their combined use might be a promising method to improve the diagnostic value of lncRNAs in cancers. 36 By following p53 activation, LINC00475 regulates levels of CDKN1A/p21, a cell cycle inhibitor and a major p53 target gene. 37 Interestingly, taurine upregulated gene 1 (TUG1), the most downregulated lncRNA in our study (Table 1) , is upregulated in hepatocellular carcinoma (HCC) tissues and promotes cell growth and apoptosis through epigenetic silencing of Kruppel-like factor 2 (KLF2). 38 To confirm the microarray results, we expanded the sample size of gastric cancer tissue and examined expression levels of RP11-555H23.1, the second most downregulated lncRNA in metabolic pathway microarray detection ( Table 1 ). The results showed consistency between these two assays ( Figure 1 ). The ROC curve evidenced this lncRNA's diagnostic value (Figure 2 ), and its sensitivity and specificity were 81% and 62%, respectively. Furthermore, expression levels of RP11-555H23.1 were related to TNM stage (Table 3 ). Since lncRNA screening was performed through metabolic pathway microarray and since the patients with earlier gastric cancer expressed much lower levels of RP11-555H23.1 than did the advanced patients (Table 3) , our results indicate that RP11-555H23.1 might alter metabolism in gastric cancer and play a role in gastric cancer initiation.
One of the weaknesses of this study is the results related to differences in the expression of RP11-555H23.1 between carcinoma tissues, which were heterogeneous with regard to cellular type and content, and adjacent "normal" tissues, which were also likely to exhibit cellular heterogeneity. As a result, an increased number of samples or more pure cells should be used in the future.
Little experimental evidence of an association with a known metabolic process was presented that would reflect the presence of gastric carcinoma. However, lncRNA species have been reported to be related to multidrug resistance and sensitivity, 39 as well as carcinogenesis. 40 In contrast to the goals of other studies, this study was focused on identifying diagnostic biomarkers.
In conclusion, lncRNAs play a role in gastric cancer through regulating metabolism, and the representative metabolic-associated lncRNA RP11-555H23.1 might represent a diagnostic biomarker in gastric cancer. 
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